We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

58 hedge funds and large institutions have $396M invested in Aclaris Therapeutics in 2016 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

156% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 9

40% more capital invested

Capital invested by funds: $284M → $396M (+$113M)

26% more funds holding

Funds holding: 46 → 58 (+12)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
58
Holders Change
+12
Holders Change %
+26.09%
% of All Funds
1.55%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
23
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$9.12M
2
DCM
Driehaus Capital Management
Illinois
+$3.88M
3
GTC
Ghost Tree Capital
New York
+$3.71M
4
EAM
Eventide Asset Management
Massachusetts
+$2.97M
5
Marshall Wace
Marshall Wace
United Kingdom
+$2.56M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$22.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.77M
3
Fidelity International
Fidelity International
Bermuda
-$2.58M
4
TC
TFS Capital
Pennsylvania
-$614K
5
Norges Bank
Norges Bank
Norway
-$357K
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
$894K +$15.7K +742 +2%
TAM
27
Tocqueville Asset Management
New York
$845K +$488K +23,000 +230%
EI
28
EAM Investors
California
$819K -$88.6K -4,175 -12%
Norges Bank
29
Norges Bank
Norway
$811K -$357K -16,830 -34%
EA
30
Emerald Acquisition
Washington
$694K – – –
Morgan Stanley
31
Morgan Stanley
New York
$690K +$569K +26,823 +23,529%
MIM
32
Monashee Investment Management
Massachusetts
$684K – – –
Charles Schwab
33
Charles Schwab
California
$629K +$17.3K +816 +3%
EEG
34
E.E. Geduld
$576K +$106K +5,000 +29%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$515K +$25.5K +1,200 +6%
Swiss National Bank
36
Swiss National Bank
Switzerland
$392K – – –
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$364K +$60.7K +2,863 +25%
TA
38
Teachers Advisors
New York
$354K -$8.44K -398 -3%
Neuberger Berman Group
39
Neuberger Berman Group
New York
$333K +$276K +13,000 New
Citadel Advisors
40
Citadel Advisors
Florida
$238K +$197K +9,303 New
EMG
41
Ellington Management Group
Connecticut
$233K +$193K +9,117 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$210K +$174K +8,192 New
SO
43
STRS Ohio
Ohio
$207K +$108K +5,100 +170%
MLICM
44
Metropolitan Life Insurance Company (MetLife)
New York
$206K +$171K +8,061 New
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$192K – – –
NFA
46
Nationwide Fund Advisors
Ohio
$147K – – –
AIG
47
American International Group
New York
$133K +$149 +7 +0.1%
BA
48
BlackRock Advisors
Delaware
$117K +$35.8K +1,686 +59%
Wells Fargo
49
Wells Fargo
California
$84K +$34.3K +1,617 +98%
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$82K +$67.9K +3,200 New
1
2
3

ACRS Hedge Fund Activity: Q3 2016 in Review

58 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2016, worth a combined $396M — up 40% from $284M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ACRS positions and 4 closed out — a net gain of 12 holders — while 23 added to existing stakes and 9 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $9.12M. The largest seller was RA Capital Management, cutting an estimated $22.9M.

  • 58 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2016, up from 46 in Q2 2016.
  • Funds reported $396M of Aclaris Therapeutics stock for Q3 2016, up 40% quarter-over-quarter.
  • 16 funds opened new Aclaris Therapeutics positions in Q3 2016 and 4 closed out, a net change of +12 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2016 was Perceptive Advisors, an estimated $9.12M added.
  • The largest Aclaris Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $22.9M sold.

Based on aggregated 13F filings for Q3 2016.